---
document_datetime: 2025-12-02 05:08:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/opfolda.html
document_name: opfolda.html
version: success
processing_time: 0.1136771
conversion_datetime: 2025-12-24 05:50:06.944893
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Opfolda

[RSS](/en/individual-human-medicine.xml/67688)

##### Authorised

This medicine is authorised for use in the European Union

miglustat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Opfolda](#news-on)
- [More information on Opfolda](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Opfolda is a medicine used in the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency), an inherited disorder in which patients have breathing difficulties and muscle weakness. It is used in combination with another medicine, cipaglucosidase alfa.

Opfolda is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but it is available as capsules of a different strength.The reference medicine for Opfolda is Zavesca.

Opfolda contains the active substance miglustat.

Expand section

Collapse section

## How is Opfolda used?

Opfolda capsules are taken by mouth approximately 1 hour but no more than 3 hours before a cipaglucosidase alfa infusion (drip).

The medicine can only be obtained with a prescription and treatment should be supervised by a doctor experienced in the management of patients with Pompe disease or similar diseases.

For more information about using Opfolda, see the package leaflet or contact your doctor or pharmacist

## How does Opfolda work?

The active substance in Opfolda, miglustat, attaches to cipaglucosidase alfa during treatment. This makes cipaglucosidase alfa more stable, so it can continue to be absorbed from the blood by the muscle cells that are affected by Pompe disease.

## What benefits of Opfolda have been shown in studies?

One main study in 125 adults with Pompe disease compared the effects of Opfolda plus cipaglucosidase alfa with alglucosidase alfa (another medicine for Pompe disease) plus placebo (a dummy treatment).

The study showed that, after one year of treatment, the distance patients could walk in six minutes improved by around 20 meters in patients treated with Opfolda plus cipaglucosidase alfa, compared with an improvement of around 8 meters in patients on alglucosidase alfa and placebo. This difference was considered clinically relevant.

## What are the risks associated with Opfolda?

For the full list of side effects and restrictions with Opfolda, see the package leaflet.

The most common side effect with Opfolda (which may affect up to 1 in 10 people) is constipation.

Opfolda must not be used by people who cannot take cipaglucosidase alfa.

## Why is Opfolda authorised in the EU?

The European Medicines Agency concluded that the effects of Opfolda in combination with cipaglucosidase alfa are clinically relevant and that their use offers an alternative treatment option for adult patients with late-onset Pompe disease. The safety profile of the combination is considered acceptable and comparable to that of alglucosidase alfa.

The Agency therefore decided that Opfolda's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Opfolda?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Opfolda have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Opfolda are continuously monitored. Suspected side effects reported with Opfolda are carefully evaluated and any necessary action taken to protect patients.

## Other information about Opfolda

Opfolda received a marketing authorisation valid throughout the EU on 26 June 2023.

Opfolda : EPAR - Medicine Overview

Reference Number: EMA/225836/2023

English (EN) (117.31 KB - PDF)

**First published:** 07/07/2023

[View](/en/documents/overview/opfolda-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-166)

български (BG) (141.3 KB - PDF)

**First published:**

07/07/2023

[View](/bg/documents/overview/opfolda-epar-medicine-overview_bg.pdf)

español (ES) (117.41 KB - PDF)

**First published:**

07/07/2023

[View](/es/documents/overview/opfolda-epar-medicine-overview_es.pdf)

čeština (CS) (138.9 KB - PDF)

**First published:**

07/07/2023

[View](/cs/documents/overview/opfolda-epar-medicine-overview_cs.pdf)

dansk (DA) (151.37 KB - PDF)

**First published:**

07/07/2023

[View](/da/documents/overview/opfolda-epar-medicine-overview_da.pdf)

Deutsch (DE) (127.17 KB - PDF)

**First published:**

07/07/2023

[View](/de/documents/overview/opfolda-epar-medicine-overview_de.pdf)

eesti keel (ET) (114.79 KB - PDF)

**First published:**

07/07/2023

[View](/et/documents/overview/opfolda-epar-medicine-overview_et.pdf)

ελληνικά (EL) (139.99 KB - PDF)

**First published:**

07/07/2023

[View](/el/documents/overview/opfolda-epar-medicine-overview_el.pdf)

français (FR) (118.22 KB - PDF)

**First published:**

07/07/2023

[View](/fr/documents/overview/opfolda-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.44 KB - PDF)

**First published:**

07/07/2023

[View](/hr/documents/overview/opfolda-epar-medicine-overview_hr.pdf)

italiano (IT) (116.53 KB - PDF)

**First published:**

07/07/2023

[View](/it/documents/overview/opfolda-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.91 KB - PDF)

**First published:**

07/07/2023

[View](/lv/documents/overview/opfolda-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.86 KB - PDF)

**First published:**

07/07/2023

[View](/lt/documents/overview/opfolda-epar-medicine-overview_lt.pdf)

magyar (HU) (137.38 KB - PDF)

**First published:**

07/07/2023

[View](/hu/documents/overview/opfolda-epar-medicine-overview_hu.pdf)

Malti (MT) (139.92 KB - PDF)

**First published:**

07/07/2023

[View](/mt/documents/overview/opfolda-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.35 KB - PDF)

**First published:**

07/07/2023

[View](/nl/documents/overview/opfolda-epar-medicine-overview_nl.pdf)

polski (PL) (140.35 KB - PDF)

**First published:**

07/07/2023

[View](/pl/documents/overview/opfolda-epar-medicine-overview_pl.pdf)

português (PT) (117.66 KB - PDF)

**First published:**

07/07/2023

[View](/pt/documents/overview/opfolda-epar-medicine-overview_pt.pdf)

română (RO) (135.96 KB - PDF)

**First published:**

07/07/2023

[View](/ro/documents/overview/opfolda-epar-medicine-overview_ro.pdf)

slovenčina (SK) (137.98 KB - PDF)

**First published:**

07/07/2023

[View](/sk/documents/overview/opfolda-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.68 KB - PDF)

**First published:**

07/07/2023

[View](/sl/documents/overview/opfolda-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.36 KB - PDF)

**First published:**

07/07/2023

[View](/fi/documents/overview/opfolda-epar-medicine-overview_fi.pdf)

svenska (SV) (124.65 KB - PDF)

**First published:**

07/07/2023

[View](/sv/documents/overview/opfolda-epar-medicine-overview_sv.pdf)

Opfolda : EPAR - Risk management plan summary

English (EN) (162.42 KB - PDF)

**First published:** 07/07/2023

[View](/en/documents/rmp-summary/opfolda-epar-risk-management-plan-summary_en.pdf)

## Product information

Opfolda : EPAR - Product Information

English (EN) (637.01 KB - PDF)

**First published:** 07/07/2023

**Last updated:** 14/02/2025

[View](/en/documents/product-information/opfolda-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-589)

български (BG) (738.47 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/bg/documents/product-information/opfolda-epar-product-information_bg.pdf)

español (ES) (653.92 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/es/documents/product-information/opfolda-epar-product-information_es.pdf)

čeština (CS) (656.33 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/cs/documents/product-information/opfolda-epar-product-information_cs.pdf)

dansk (DA) (804.57 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/da/documents/product-information/opfolda-epar-product-information_da.pdf)

Deutsch (DE) (781.4 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/de/documents/product-information/opfolda-epar-product-information_de.pdf)

eesti keel (ET) (665.78 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/et/documents/product-information/opfolda-epar-product-information_et.pdf)

ελληνικά (EL) (693.61 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/el/documents/product-information/opfolda-epar-product-information_el.pdf)

français (FR) (697.25 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/fr/documents/product-information/opfolda-epar-product-information_fr.pdf)

hrvatski (HR) (677.99 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/hr/documents/product-information/opfolda-epar-product-information_hr.pdf)

íslenska (IS) (876.96 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/is/documents/product-information/opfolda-epar-product-information_is.pdf)

italiano (IT) (750.72 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/it/documents/product-information/opfolda-epar-product-information_it.pdf)

latviešu valoda (LV) (679.18 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/lv/documents/product-information/opfolda-epar-product-information_lv.pdf)

lietuvių kalba (LT) (657.88 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/lt/documents/product-information/opfolda-epar-product-information_lt.pdf)

magyar (HU) (682.62 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/hu/documents/product-information/opfolda-epar-product-information_hu.pdf)

Malti (MT) (665.49 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/mt/documents/product-information/opfolda-epar-product-information_mt.pdf)

Nederlands (NL) (844.48 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/nl/documents/product-information/opfolda-epar-product-information_nl.pdf)

norsk (NO) (674.66 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/no/documents/product-information/opfolda-epar-product-information_no.pdf)

polski (PL) (726.19 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/pl/documents/product-information/opfolda-epar-product-information_pl.pdf)

português (PT) (656.57 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/pt/documents/product-information/opfolda-epar-product-information_pt.pdf)

română (RO) (680.38 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/ro/documents/product-information/opfolda-epar-product-information_ro.pdf)

slovenčina (SK) (695.07 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/sk/documents/product-information/opfolda-epar-product-information_sk.pdf)

slovenščina (SL) (679.77 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/sl/documents/product-information/opfolda-epar-product-information_sl.pdf)

Suomi (FI) (671.21 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/fi/documents/product-information/opfolda-epar-product-information_fi.pdf)

svenska (SV) (667.07 KB - PDF)

**First published:**

07/07/2023

**Last updated:**

14/02/2025

[View](/sv/documents/product-information/opfolda-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0010/G 24/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Opfolda : EPAR - All authorised presentations

English (EN) (49.48 KB - PDF)

**First published:** 07/07/2023

[View](/en/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-675)

български (BG) (65.91 KB - PDF)

**First published:**

07/07/2023

[View](/bg/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_bg.pdf)

español (ES) (64.4 KB - PDF)

**First published:**

07/07/2023

[View](/es/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.33 KB - PDF)

**First published:**

07/07/2023

[View](/cs/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (55.06 KB - PDF)

**First published:**

07/07/2023

[View](/da/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (64.45 KB - PDF)

**First published:**

07/07/2023

[View](/de/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.82 KB - PDF)

**First published:**

07/07/2023

[View](/et/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (93.42 KB - PDF)

**First published:**

07/07/2023

[View](/el/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_el.pdf)

français (FR) (65.41 KB - PDF)

**First published:**

07/07/2023

[View](/fr/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (61.2 KB - PDF)

**First published:**

07/07/2023

[View](/hr/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (64.32 KB - PDF)

**First published:**

07/07/2023

[View](/is/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_is.pdf)

italiano (IT) (64.21 KB - PDF)

**First published:**

07/07/2023

[View](/it/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (93.14 KB - PDF)

**First published:**

07/07/2023

[View](/lv/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (77.6 KB - PDF)

**First published:**

07/07/2023

[View](/lt/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (78.31 KB - PDF)

**First published:**

07/07/2023

[View](/hu/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (77.57 KB - PDF)

**First published:**

07/07/2023

[View](/mt/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (63.66 KB - PDF)

**First published:**

07/07/2023

[View](/nl/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (63.95 KB - PDF)

**First published:**

07/07/2023

[View](/no/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_no.pdf)

polski (PL) (92.96 KB - PDF)

**First published:**

07/07/2023

[View](/pl/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_pl.pdf)

português (PT) (63.43 KB - PDF)

**First published:**

07/07/2023

[View](/pt/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_pt.pdf)

română (RO) (92.11 KB - PDF)

**First published:**

07/07/2023

[View](/ro/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (92.38 KB - PDF)

**First published:**

07/07/2023

[View](/sk/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (71.78 KB - PDF)

**First published:**

07/07/2023

[View](/sl/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (63.37 KB - PDF)

**First published:**

07/07/2023

[View](/fi/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (65.21 KB - PDF)

**First published:**

07/07/2023

[View](/sv/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Opfolda Active substance miglustat International non-proprietary name (INN) or common name miglustat Therapeutic area (MeSH) Glycogen Storage Disease Type II Anatomical therapeutic chemical (ATC) code A16AX06

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid ?- glucosidase [GAA] deficiency).

## Authorisation details

EMA product number EMEA/H/C/005695 Marketing authorisation holder

Amicus Therapeutics Europe Limited

Block 1, Blanchardstown Corporate Park Ballycoolin Road Blanchardstown Dublin 15 D15 AKK1 Ireland

Opinion adopted 26/04/2023 Marketing authorisation issued 26/06/2023 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Opfolda: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (166.92 KB - PDF)

**First published:** 22/09/2023

**Last updated:** 14/02/2025

[View](/en/documents/procedural-steps-after/opfolda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Opfolda : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/794405/2022

English (EN) (1.43 MB - PDF)

**First published:** 07/07/2023

[View](/en/documents/assessment-report/opfolda-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Opfolda

Adopted

Reference Number: EMA/CHMP/794403/2022

English (EN) (151.56 KB - PDF)

**First published:** 26/04/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-opfolda_en.pdf)

#### News on Opfolda

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

#### More information on Opfolda

- [A GLOBAL PROSPECTIVE OBSERVATIONAL REGISTRY OF PATIENTS WITH POMPE DISEASE - post-authorisation study](https://catalogues.ema.europa.eu/study/107300)

**This page was last updated on** 14/02/2025

## Share this page

[Back to top](#main-content)